Tags

Type your tag names separated by a space and hit enter

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
Braz J Psychiatry 2008; 30(3):271-80BJ

Abstract

OBJECTIVE

The aim of this review is to describe the historical development of research on cannabidiol.

METHOD

This review was carried out on reports drawn from Medline, Web of Science and SciELO.

DISCUSSION

After the elucidation of the chemical structure of cannabidiol in 1963, the initial studies showed that cannabidiol was unable to mimic the effects of Cannabis. In the 1970's the number of publications on cannabidiol reached a first peak, having the research focused mainly on the interaction with delta9-THC and its antiepileptic and sedative effects. The following two decades showed lower degree of interest, and the potential therapeutic properties of cannabidiol investigated were mainly the anxiolytic, antipsychotic and on motor diseases effects. The last five years have shown a remarkable increase in publications on cannabidiol mainly stimulated by the discovery of its anti-inflammatory, anti-oxidative and neuroprotective effects. These studies have suggested a wide range of possible therapeutic effects of cannabidiol on several conditions, including Parkinson's disease, Alzheimer's disease, cerebral ischemia, diabetes, rheumatoid arthritis, other inflammatory diseases, nausea and cancer.

CONCLUSION

In the last 45 years it has been possible to demonstrate that CBD has a wide range of pharmacological effects, many of which being of great therapeutic interest, but still waiting to be confirmed by clinical trials.

Authors+Show Affiliations

Department of Neurology, Psychiatry and Medical Psychology, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil. awzuardi@fmrp.usp.br

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18833429

Citation

Zuardi, Antonio Waldo. "Cannabidiol: From an Inactive Cannabinoid to a Drug With Wide Spectrum of Action." Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999), vol. 30, no. 3, 2008, pp. 271-80.
Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Braz J Psychiatry. 2008;30(3):271-80.
Zuardi, A. W. (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999), 30(3), pp. 271-80.
Zuardi AW. Cannabidiol: From an Inactive Cannabinoid to a Drug With Wide Spectrum of Action. Braz J Psychiatry. 2008;30(3):271-80. PubMed PMID: 18833429.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. A1 - Zuardi,Antonio Waldo, PY - 2008/03/07/received PY - 2008/04/17/accepted PY - 2008/10/4/pubmed PY - 2009/7/25/medline PY - 2008/10/4/entrez SP - 271 EP - 80 JF - Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) JO - Braz J Psychiatry VL - 30 IS - 3 N2 - OBJECTIVE: The aim of this review is to describe the historical development of research on cannabidiol. METHOD: This review was carried out on reports drawn from Medline, Web of Science and SciELO. DISCUSSION: After the elucidation of the chemical structure of cannabidiol in 1963, the initial studies showed that cannabidiol was unable to mimic the effects of Cannabis. In the 1970's the number of publications on cannabidiol reached a first peak, having the research focused mainly on the interaction with delta9-THC and its antiepileptic and sedative effects. The following two decades showed lower degree of interest, and the potential therapeutic properties of cannabidiol investigated were mainly the anxiolytic, antipsychotic and on motor diseases effects. The last five years have shown a remarkable increase in publications on cannabidiol mainly stimulated by the discovery of its anti-inflammatory, anti-oxidative and neuroprotective effects. These studies have suggested a wide range of possible therapeutic effects of cannabidiol on several conditions, including Parkinson's disease, Alzheimer's disease, cerebral ischemia, diabetes, rheumatoid arthritis, other inflammatory diseases, nausea and cancer. CONCLUSION: In the last 45 years it has been possible to demonstrate that CBD has a wide range of pharmacological effects, many of which being of great therapeutic interest, but still waiting to be confirmed by clinical trials. SN - 1516-4446 UR - https://www.unboundmedicine.com/medline/citation/18833429/abstract/Cannabidiol:_from_an_inactive_cannabinoid_to_a_drug_with_wide_spectrum_of_action_ L2 - http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462008000300015&lng=en&nrm=iso&tlng=en DB - PRIME DP - Unbound Medicine ER -